ABSTRACT Introduction: Direct oral anticoagulants (DOACs) may be regarded as some of
the most successful innovations in recent times. These drugs which were specifically …

Direct oral anticoagulants are now recommended by major guidelines as first-choice agents
for both stroke prevention in non-valvular atrial fibrillation and treatment/prevention of …

Since 2008, the direct-acting oral anticoagulants (DOACs) have expanded the therapeutic
options of cardiovascular diseases with recognized clinical and epidemiological impact …

Direct-acting oral anticoagulants (DOACs) were claimed to cause a potential paradigm shift
in the therapeutic scenario of patients requiring short-and long-term anticoagulation, by …

Non-vitamin K oral anticoagulants, also known as direct-acting oral anticoagulants (DOACs),
have entered the market in 2008 with the expected breakthrough potential of circumventing …

Direct oral anticoagulants (DOACs) have become the recommended first choice
anticoagulant agent for treatment of acute venous thromboembolism (VTE) in non-cancer …

Direct oral anticoagulants (DOACs) have been marketed in the United States since 2010.
While numerous large-scale prospective phase 3 outcomes studies have documented the …

Objectives The aim of this study was to compare effectiveness and safety of low-strength and
high-strength direct oral anticoagulants (DOACs) with warfarin in the Australian Veteran …

Aim Direct oral anticoagulants (DOACs) have shown noninferiority to warfarin for stroke
prevention in nonvalvular atrial fibrillation (AF) and a more promising safety profile …

Vitamin K antagonists, such as warfarin, have been the anticoagulants of choice for many
years for patients with AF and other thrombotic conditions. The introduction of direct oral …